Futureproofing Post-Approval Compliance By Integrating LQPPV And Lifecycle Management With Applied AI

By Jay Gandecha, Senior Director, Regulatory Affairs; and Ana Pedro Jesuíno, Director, Marketed Product Safety

Though approval is a major accomplishment for a drug, it marks the start of a new and increasingly complex journey. Post-approval and safety functions must adapt to accommodate shifting volumes as safety signals emerge and labels evolve. At the post-approval stage, global governance, legal obligations, volume variations, and market-specific expectations all converge. To accommodate this, sponsors must strategically design their operating model to maintain speed, flexibility, and compliance.

Regulators now expect high-quality, traceable, data-driven submissions that have minimal inconsistencies across markets. By leveraging a synergistic operating model, a sponsor’s safety and regulatory functions are brought under a single umbrella with shared decision cycles, templates, and evidence, increasing synergy and protecting compliance. Download the full article to learn more about the benefits of leveraging synergistic operating model to protect your product and patients.